Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Champions Oncology, Inc.NASDAQ: CSBR

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Jan 2026

Weighted avg shares (diluted) declines year over year

Q3 FY2026 weighted avg shares (diluted) of 13.89M shares fell 3.3% year over year, behind the -0.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at +0.3% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -3.3% toward the trailing-twelve-month pace of -0.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJan 2026
13.89M-3.9% QoQ
Last fiscal yearApr 2025
14.27M+5.3% YoY
LTMJan 2026
13.97M-0.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.3%——
1 year+5.3%——
3-year CAGR+0.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
14.27M USD
Year-over-year change
+5.3%
4-year CAGR
-0.5%

Weighted Avg Shares (Diluted) vs competitors

How CSBR compares with its peers on the latest reported figures

  • CSBR's LTM Jan 2026 weighted avg shares (diluted) of 13.97M shares is the 8th highest of the 10 companies compared; the peer median is 24.5M shares.
  • Its year-over-year change of -0.2% is the 8th highest of 10, against a peer median of +3.8%.
  • Over three fiscal years its annual growth of +0.3% compares with a peer median of +15.0%.
CSBR Competitors Peer median
Weighted Avg Shares (Diluted) for CSBR and competitors
Company Period LTM YoY 3-year CAGR
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
IFRXInflaRx N.V.LTM Mar 202668.86M +14.8%+15.0%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 202642.44M +3.8%+2.8%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 202624.5M +1.8%+11.6%
KLRSKalaris Therapeutics IncLTM Mar 202621.01M +341.4%+66.1%
IMAImageneBio IncLTM Mar 202619.79M -59.0%-48.8%
CSBRChampions Oncology, Inc.LTM Jan 202613.97M -0.2%+0.3%
ATRAAtara Biotherapeutics, Inc.LTM Mar 202613.17M +49.9%+46.1%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding CSBR) 24.5M+3.8%+15.0%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue41.04M49.11M53.87M50.16M56.94M
Cost of Revenue21.45M23.63M29.53M29.4M28.39M
Gross Profit19.59M25.48M24.34M20.75M28.56M
Gross Margin47.7%51.9%45.2%41.4%50.1%
Research & Development7.2M9.37M11.55M9.54M6.83M
Selling, General & Admin12.03M15.5M17.24M18.13M16.88M
Operating Expenses19.23M24.87M28.79M27.68M23.71M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
EBITDA1.55M2.21M(3.02M)(5.44M)6.27M
EBITDA Margin3.8%4.5%-5.6%-10.8%11.0%
Operating Income366K607K(4.45M)(6.92M)4.85M
Operating Margin0.9%1.2%-8.3%-13.8%8.5%
Interest Income00000
Interest Expense00000
Other Income / Expenses71K(24K)(818K)(387K)(220K)
Income Before Tax437K583K(5.27M)(7.31M)4.63M
Pre-Tax Margin1.1%1.2%-9.8%-14.6%8.1%
Income Tax Expense75K35K68K(32K)(75K)
Net Income362K548K(5.34M)(7.28M)4.7M
Net Margin0.9%1.1%-9.9%-14.5%8.3%
EPS (Basic)0.030.04(0.39)(0.54)0.34
EPS (Diluted)0.020.04(0.39)(0.54)0.33
Weighted Avg Shares13.14M13.2M13.54M13.55M13.66M
Weighted Avg Shares (Diluted)14.57M14.16M13.54M13.55M14.27M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.